Literature DB >> 33183957

Cytokines in oncolytic virotherapy.

Jonathan G Pol1, Samuel T Workenhe2, Prathyusha Konda3, Shashi Gujar4, Guido Kroemer5.   

Abstract

Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail to eliminate malignant targets. By inducing immunogenic cancer cell death, oncolytic viruses profoundly reshape the tumor microenvironment. They trigger the local spread of danger signals and tumor-associated (as well as viral) antigens, thus attracting antigen-presenting cells, promoting the activation and expansion of lymphocytic populations, facilitating their infiltration in the tumor bed, and reinvigorating cytotoxic immune activity. The present review recapitulates key chemokines, growth factors and other cytokines that orchestrate this ballet of antitumoral leukocytes upon oncolytic virotherapy.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Chemokines; Growth factors; Interferons; Interleukins; Oncolytic virus

Year:  2020        PMID: 33183957     DOI: 10.1016/j.cytogfr.2020.10.007

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  11 in total

Review 1.  Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications.

Authors:  Jhalak Dholakia; Alexander C Cohen; Charles A Leath; Elizabeth T Evans; Ronald D Alvarez; Premal H Thaker
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

2.  Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing.

Authors:  Divya Ravirala; Guangsheng Pei; Zhongming Zhao; Xiaoliu Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-10-30       Impact factor: 6.968

3.  NK Cell Effector Functions and Bystander Tumor Cell Killing in Immunovirotherapy.

Authors:  Alessia Floerchinger; Christine E Engeland
Journal:  Methods Mol Biol       Date:  2022

4.  Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.

Authors:  Qiuman Wang; Xinyue Ma; Huan Wu; Chen Zhao; Jingying Chen; Rongrong Li; Shi Yan; Yingwei Li; Qing Zhang; Kun Song; Cunzhong Yuan; Beihua Kong
Journal:  Oncoimmunology       Date:  2022-07-01       Impact factor: 7.723

5.  Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors.

Authors:  Yinghan Su; Jiang Li; Weidan Ji; Gang Wang; Lin Fang; Qin Zhang; Lin Ang; Min Zhao; Yuan Sen; Lei Chen; Junnian Zheng; Changqing Su; Lunxiu Qin
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

6.  TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy.

Authors:  Miriam Valenzuela-Cardenas; Cody Gowan; Parker Dryja; Mee Y Bartee; Eric Bartee
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

Review 7.  Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.

Authors:  Johannes P W Heidbuechel; Christine E Engeland
Journal:  J Hematol Oncol       Date:  2021-04-16       Impact factor: 17.388

Review 8.  Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy.

Authors:  Masmudur M Rahman; Grant McFadden
Journal:  Cancers (Basel)       Date:  2021-10-29       Impact factor: 6.639

Review 9.  Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.

Authors:  Yaomei Tian; Daoyuan Xie; Li Yang
Journal:  Signal Transduct Target Ther       Date:  2022-04-06

Review 10.  Clinical Application of Cytokines in Cancer Immunotherapy.

Authors:  Yi Qiu; Mengxi Su; Leyi Liu; Yiqi Tang; Yuan Pan; Jianbo Sun
Journal:  Drug Des Devel Ther       Date:  2021-05-27       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.